Evidence map›Paper›PMID 29670370›Full record

ArticleOncoTargets and therapy2018

Fabrication of ultrasmall WS

Wenyun Liao, Li Zhang, Yunhua Zhong, Yuan Shen, Changlin Li, Na An

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Advancement in Nanotablet Research: An Overview.Recent advances in drug delivery and formulation · 2026
    Review
  2. WSACS omega · 2022
    Article
  3. Review
  4. Conventional Nanosized Drug Delivery Systems for Cancer Applications.Advances in experimental medicine and biology · 2021
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenyun LiaoDepartment of Emergency, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, People's Republic of China.
Li ZhangDepartment of Emergency, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, People's Republic of China.
Yunhua ZhongDepartment of Geriatrics, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, People's Republic of China.
Yuan ShenDepartment of Emergency, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, People's Republic of China.
Changlin LiDepartment of Emergency, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, People's Republic of China.
Na AnDepartment of Emergency, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe consolidation of different therapies into a single nanoplatform has shown great promise for synergistic tumor treatment. In this study, a multifunctional platform by WS MATERIALS AND

methodsThe structure, light-mediated drug release behavior, photothermal effect, and synergistic therapeutic efficiency of PMOs-DOX@WQDs to HCT-116 colon cancer cells were investigated. The thioether-bridged PMOs exhibit a high DOX loading capacity of 66.7 μg mg

resultsIt was confirmed that PMOs-DOX@WQDs exhibit remarkable photothermal effect and light-triggered faster release of DOX. More importantly, it was reasonable to attribute the efficient anti-tumor efficiency of PMOs-DOX@WQDs.

conclusionThe in vitro experimental results confirm that the fabricated nanocarrier exhibits a significant synergistic effect, resulting in a higher efficacy to kill cancer cells. Therefore, the WQD-coated PMOs present promising applications in cancer therapy.

Indexed as

chemo-photothermal therapydrug deliveryperiodic mesoporous organosilicaWS2 quantum dots

Identifiers

PMID29670370
PMCPMC5896670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.